ArticleNeoplasia (New York, N.Y.)2013

Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.

Dustin M Walters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.